Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986886 | 0.93 | NPY2R (0.39) | KCNH2NPY2R | |
| SCHEMBL3657660 | 0.88 | RAB9A (0.40) | — | |
| SCHEMBL2980866 | 0.83 | HDAC1 (0.39) | KCNH2 | |
| SCHEMBL2973525 | 0.82 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL2978680 | 0.82 | NPY2R (0.39) | KCNH2NPY2R | |
| SCHEMBL2984550 | 0.82 | P2RX7 (0.42) | KCNH2NPY2R | |
| SCHEMBL2982195 | 0.81 | NPY2R (0.41) | KCNH2NPY2R | |
| SCHEMBL2973523 | 0.81 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL2972354 | 0.79 | SMN1; SMN2 (0.47) | NPY2R | |
| SCHEMBL2981578 | 0.76 | NPY2R (0.44) | KCNH2NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786155-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| EP-2212295-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050201-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099244-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099244-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | KCNH2 1653/4885NPY2R 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.